Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by C WorldWide Group Holding A S

C WorldWide Group Holding A S lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 22.1% during the 4th quarter, Holdings Channel reports. The firm owned 105,809 shares of the company’s stock after selling 30,000 shares during the quarter. C WorldWide Group Holding A S’s holdings in Krystal Biotech were worth $16,576,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in KRYS. Segall Bryant & Hamill LLC grew its stake in Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp grew its stake in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Franklin Resources Inc. grew its stake in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Braidwell LP grew its stake in Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its stake in Krystal Biotech by 39.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after purchasing an additional 44,646 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

KRYS has been the topic of several research analyst reports. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, February 19th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $210.00.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Trading Up 2.9 %

NASDAQ KRYS opened at $187.86 on Monday. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34. The stock has a 50-day moving average of $157.85 and a 200 day moving average of $175.26.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.30 EPS. Equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).